Patents by Inventor Roger Schofield Newton

Roger Schofield Newton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FIXED DOSE COMBINATIONS AND FORMULATIONS COMPRISING ETC1002 AND ONE OR MORE STATINS AND METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE
    Publication number: 20240148681
    Abstract: Disclosed herein are compositions comprising fixed doses of ETC-1002 and one or more statins. Also disclosed herein are methods for using fixed doses of ETC-1002 and one or more statins. Uses include methods of treating cardiovascular disease or reducing the risk of cardiovascular disease in a subject. Uses also include methods of treating hypercholesterolemia in a subject.
    Type: Application
    Filed: May 31, 2023
    Publication date: May 9, 2024
    Inventors: Roger Schofield Newton, Noah Laban Rosenberg, Diane Elaine MacDougall
  • Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
    Patent number: 11744816
    Abstract: Disclosed herein are compositions comprising fixed doses of ETC-1002 and Ezetimibe. Also disclosed herein are methods for using fixed doses of ETC-1002 and Ezetimibe. Uses include methods of treating cardiovascular disease or reducing the risk of cardiovascular disease in a subject. Uses also include methods of treating hypercholesterolemia in a subject.
    Type: Grant
    Filed: December 29, 2020
    Date of Patent: September 5, 2023
    Assignee: Esperion Therapeutics, Inc.
    Inventors: Roger Schofield Newton, Noah Laban Rosenberg, Diane Elaine MacDougall
  • Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease
    Patent number: 11737995
    Abstract: Methods for treating or preventing kidney diseases and fibrosis, such as chronic kidney disease (CKD), kidney fibrosis, heart fibrosis, uterine fibrosis, and cystic fibrosis, with compounds of Formulae (I), (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH), (IJ), (II), (III), (IIIA), and (IIIB); pharmaceutically acceptable salts and solvates thereof; and compositions thereof.
    Type: Grant
    Filed: January 24, 2022
    Date of Patent: August 29, 2023
    Assignee: Espervita Therapeutics, Inc.
    Inventors: Daniela Carmen Oniciu, Gregory R. Steinberg, Spencer Heaton, Roger Schofield Newton, James Stuart Vincent Lally, Jaya Gautam
  • FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE
    Publication number: 20230113853
    Abstract: This invention provides methods for treating or preventing kidney diseases and fibrosis, such as chronic kidney disease (CKD), kidney fibrosis, heart fibrosis, uterine fibrosis, and cystic fibrosis, with compounds of Formulae (I), (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH), (IJ), (II), (III), (IIIA), and (IIIB); pharmaceutically acceptable salts and solvates thereof; and compositions thereof.
    Type: Application
    Filed: January 24, 2022
    Publication date: April 13, 2023
    Inventors: Daniela Carmen ONICIU, Gregory R. STEINBERG, Spencer HEATON, Roger Schofield NEWTON, James Stuart Vincent LALLY, Jaya GAUTAM
  • FIXED DOSE COMBINATIONS AND FORMULATIONS COMPRISING ETC1002 AND ONE OR MORE STATINS AND METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE
    Publication number: 20220110904
    Abstract: Disclosed herein are compositions comprising fixed doses of ETC-1002 and one or more statins. Also disclosed herein are methods for using fixed doses of ETC-1002 and one or more statins. Uses include methods of treating cardiovascular disease or reducing the risk of cardiovascular disease in a subject. Uses also include methods of treating hypercholesterolemia in a subject.
    Type: Application
    Filed: September 2, 2021
    Publication date: April 14, 2022
    Inventors: Roger Schofield Newton, Noah Laban Rosenberg, Diane Elaine MacDougall
  • FIXED DOSE COMBINATIONS AND FORMULATIONS COMPRISING ETC1002 AND EZETIMIBE AND METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE
    Publication number: 20210361605
    Abstract: Disclosed herein are compositions comprising fixed doses of ETC-1002 and Ezetimibe. Also disclosed herein are methods for using fixed doses of ETC-1002 and Ezetimibe. Uses include methods of treating cardiovascular disease or reducing the risk of cardiovascular disease in a subject. Uses also include methods of treating hypercholesterolemia in a subject.
    Type: Application
    Filed: December 29, 2020
    Publication date: November 25, 2021
    Inventors: Roger Schofield Newton, Noah Rosenberg, Diane Elaine MacDougall
  • Fixed dose combinations and formulations comprising ETC1002 and one or more statins and methods of treating or reducing cardiovascular disease
    Patent number: 11116739
    Abstract: Disclosed herein are compositions comprising fixed doses of ETC-1002 and one or more statins. Also disclosed herein are methods for using fixed doses of ETC-1002 and one or more statins. Uses include methods of treating cardiovascular disease or reducing the risk of cardiovascular disease in a subject. Uses also include methods of treating hypercholesterolemia in a subject.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: September 14, 2021
    Inventors: Roger Schofield Newton, Noah Laban Rosenberg, Diane Elaine MacDougall
  • Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
    Patent number: 10912751
    Abstract: Disclosed herein are compositions comprising fixed doses of ETC-1002 and Ezetimibe. Also disclosed herein are methods for using fixed doses of ETC-1002 and Ezetimibe. Uses include methods of treating cardiovascular disease or reducing the risk of cardiovascular disease in a subject. Uses also include methods of treating hypercholesterolemia in a subject.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: February 9, 2021
    Assignee: Esperion Therapeutics, Inc.
    Inventors: Roger Schofield Newton, Noah Laban Rosenberg, Diane Elaine MacDougall
  • Fixed Dose Combinations and Formulations Comprising ETC1002 and One or More Statins and Methods of Treating or Reducing Cardiovascular Disease
    Publication number: 20180078518
    Abstract: Disclosed herein are compositions comprising fixed doses of ETC-1002 and one or more statins. Also disclosed herein are methods for using fixed doses of ETC-1002 and one or more statins. Uses include methods of treating cardiovascular disease or reducing the risk of cardiovascular disease in a subject. Uses also include methods of treating hypercholesterolemia in a subject.
    Type: Application
    Filed: March 16, 2016
    Publication date: March 22, 2018
    Inventors: Roger Schofield Newton, Noah Laban Rosenberg, Diane Elaine MacDougall
  • Fixed Dose Combinations and Formulations Comprising ETC1002 and Ezetimibe and Methods of Treating or Reducing the Risk of Cardiovascular Disease
    Publication number: 20180064671
    Abstract: Disclosed herein are compositions comprising fixed doses of ETC-1002 and Ezetimibe. Also disclosed herein are methods for using fixed doses of ETC-1002 and Ezetimibe. Uses include methods of treating cardiovascular disease or reducing the risk of cardiovascular disease in a subject. Uses also include methods of treating hypercholesterolemia in a subject.
    Type: Application
    Filed: March 14, 2016
    Publication date: March 8, 2018
    Inventors: Roger Schofield Newton, Noah Laban Rosenberg, Diane Elaine MacDougall
  • Calcium Dicarboxylate Ethers
    Publication number: 20140012042
    Abstract: The invention is a pharmaceutical composition comprising a carboxyalkylether which lowers triglycerides and elevated HDL, and a statin which inhibits HMG-CoA reductase, thereby reducing LDL, said composition being useful for treating vascular diseases.
    Type: Application
    Filed: September 11, 2013
    Publication date: January 9, 2014
    Applicant: Warner-Lambert Company, LLC
    Inventors: Charles Larry Bisgaier, Roger Schofield Newton
  • Statin-carboxyalkylether combinations
    Patent number: 8557835
    Abstract: The invention is a pharmaceutical composition comprising a carboxyalkylether which lowers triglycerides and elevated HDL, and a statin which inhibits HMG-CoA reductase, thereby reducing LDL, said composition being useful for treating vascular diseases.
    Type: Grant
    Filed: December 20, 2007
    Date of Patent: October 15, 2013
    Assignee: Warner-Lambert Company, LLC
    Inventors: Charles Larry Bisgaier, Roger Schofield Newton
  • Statin-Carboxyalkylether Combinations
    Publication number: 20090118317
    Abstract: The invention is a pharmaceutical composition comprising a carboxyalkylether which lowers triglycerides and elevated HDL, and a statin which inhibits HMG-CoA reductase, thereby reducing LDL, said composition being useful for treating vascular diseases.
    Type: Application
    Filed: December 20, 2007
    Publication date: May 7, 2009
    Inventors: Charles Larry Bisgaier, Roger Schofield Newton
  • Statin-MMP inhibitor combinations
    Publication number: 20040176393
    Abstract: The invention is a pharmaceutical composition comprising an MMP inhibitor and a statin, said composition being useful for treating vascular diseases.
    Type: Application
    Filed: April 22, 2003
    Publication date: September 9, 2004
    Inventors: Roger Schofield Newton, Bruce David Roth
  • Statin-Lp(a) inhibitor combinations
    Publication number: 20040092574
    Abstract: The invention is a pharmaceutical composition comprising an Lp(a) inhibitor and a statin which inhibits HMG-CoA reductase, said composition being useful for treating vascular diseases.
    Type: Application
    Filed: August 25, 2003
    Publication date: May 13, 2004
    Inventors: Charles Larry Bisgaier, Roger Schofield Newton, Randy Ranjee Ramharack
  • Statin-carboxyalkylether combinations
    Publication number: 20030105154
    Abstract: The invention is a pharmaceutical composition comprising a carboxyalkylether which lowers triglycerides and elevated HDL, and a statin which inhibits HMG-CoA reductase, thereby reducing LDL, said composition being useful for treating vascular diseases.
    Type: Application
    Filed: September 17, 2002
    Publication date: June 5, 2003
    Inventors: Charles Larry Bisgaier, Roger Schofield Newton
  • Combinations of protein farnesyltransferase and HMG CoA reductase inhibitors and their use to treat cancer
    Patent number: 6492410
    Abstract: Novel combinations of inhibitors of protein farnesyltransferase enzymes and HMG CoA reductases enzymes are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in preventing or treating cancer, restenosis, psoriasis, endometriosis, atherosclerosis, or viral infections.
    Type: Grant
    Filed: November 6, 2000
    Date of Patent: December 10, 2002
    Assignee: Warner-Lambert Company
    Inventors: Judith Leopold, Roger Schofield Newton
  • Statin-carboxyalkylether combinations
    Publication number: 20020103252
    Abstract: The invention is a pharmaceutical composition comprising a carboxyalkylether which lowers triglycerides and elevated HDL, and a statin which inhibits HMG-CoA reductase, thereby reducing LDL, said composition being useful for treating vascular diseases.
    Type: Application
    Filed: October 24, 2001
    Publication date: August 1, 2002
    Inventors: Charles Larry Bisgaier, Roger Schofield Newton
  • Statin-MMP inhibitor combinations
    Publication number: 20020049237
    Abstract: The invention is a pharmaceutical composition comprising an MMP inhibitor and a statin, said composition being useful for treating vascular diseases.
    Type: Application
    Filed: October 12, 2001
    Publication date: April 25, 2002
    Inventors: Roger Schofield Newton, Bruce David Roth
  • Inhibition of lipoprotein oxidation
    Patent number: 6362236
    Abstract: Hydroxylated derivatives of cholesterol lowering agents inhibit the oxidation of lipoproteins, and are thus useful for preventing the progression of atherogenesis and resultant vascular diseases, including heart attacks.
    Type: Grant
    Filed: February 7, 2000
    Date of Patent: March 26, 2002
    Assignee: Warner-Lambert Company
    Inventors: Michael Aviram, Charles Larry Bisgaier, Roger Schofield Newton, Mira Rosenblat